Changes in the interpretation of the results of susceptibility testing of fungi
Abstract
The incidence of fungal infections is increasing together with the growing number of immunocompromised patients. For successful treatment it is necessary to select the optimal dose of a specific antifungal agent based on the in vitrosusceptibility testing according to the microdilution method by CLSI (Clinical and Laboratory Standards Institute) or EUCAST (European Committee on Antimicrobial Susceptibility Testing). All of the susceptibility testing results in Slovenia were processed and interpreted according to CLSI, but gradually we will start using the EUCAST system, which brings certain differences in methodology that shorten the incubation time by 24 hours and bring some changes in the interpretation of MICs (Minimal Inhibitory Concentration).
Downloads
References
Alastruey-Izquierdo A, Cuenca-Estrella M. EUCAST and CLSI: how to assess in vitro susceptibility and clinical resistance. Curr Fungal Infect Rep 2012; 6: 229–34.
European Committee on Antimicrobial SusceptibilityTesting. Setting breakpoints for new antimicrobial agents, EUCAST SOP 1.0, 2010. Dosegljivo 22. Marca 2013 s spletne strani: http://www.eucast.org.
Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007; 20: 391–408.
Mouton JW, Dudiey MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55: 601–7.
Mouton JW, Brown DFJ, Apfalter P, Cantón R, Giske CG, Ivanova M, et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 2012; 18: E37-E45.
Roberts JA, Kirkpatrick CMJ, Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother 2011; 66: 227–31.
Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, et al. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and threetriazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 2009 47: 3142–6.
Rodriguez-Tudela JL, Donnelly JP, Pfaller MA, Chryssantou E, Warn P, Denning DW, et al. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E. Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol 2007; 45: 109–11.
Calvo E, Javier Pastor F, Sutton DA, Fothergill AW, Rinaldi MG, Salas V, Guarro J. Are epidemiologic cut-off values predictors of the in vivo efficacy of azoles in experimental aspergillosis? Diagn Microbiol Infect Dis 2012; 74: 158–65.
Rodriguez-Tudela JL, Arendrup MC, Cuenca--Estrella M, Donnelly JP, Lass-Flörl C.EUCAST breakpoints for antifungals. Drug News Perspect 2010; 23: 93.
Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monzon A, Cuenca--Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008; 52: 2468–72.
Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, Pfaller MA, Rinaldi M., Rodriguez-Tudela JL, Verweij PE. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005; 43: 3884–9.
Chryssanthou E, Cuenca‐Estrella M. Comparison of the EUCAST‐AFST broth dilution method with the CLSI reference broth dilution method (M38‐A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp. Clin Microbiol Infect 2006; 12: 901–4.
Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235–47.
Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH . Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005; 49: 3171–7.
Cuesta I, Bielza C, Larranaga P, Cuenca-Estrella M, Laguna F, Rodriguez-Pardo D, et al. Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2009; 53: 2949–2954.
Cuesta I, Bielza C, Cuenca-Estrella M, Larranaga P, Rodriguez-Tudela JL. Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrob Agents Chemother 2010; 54: 1541–6.
Arendrup MC, Kahlmeter G, Rodriguez-Tudela JL, Donnelly JP. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob Agents Chemother 2009; 53: 1628–9.
European Committee on Antimicrobial Susceptibility Testing. EUCAST Antifungal Clinical Breakpoint Table v. 6.1, 2013. Dosegljivo 8. Aprila 2013 s spletne strani: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Antifungal_breakpoints_v_6.1.pdf.
Kanafani ZA, Perfect JR. Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008; 46: 120–8.
Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125: S3-S13.
Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401–14.
Espinel-Ingroff A, Cuenca-Estrella M, Cantón E. EUCAST and CLSI: Working together towards a harmonized method for antifungal susceptibility testing.“ Curr Fungal Infect Rep 2013; 7: 59–67.
Espinel-Ingroff A, Cantón E, Pemán J. Antifungal susceptibility testing of filamentous fungi. Curr Fungal Infect Rep 2012; 6: 41–50.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
